載入中
NASDAQHealthcareMedical - Healthcare Information Services
最新資料
US$2.245
−US$0.095 · -4.06%
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
前收盤價
US$2.245
−US$0.095 · -4.06%
盤後
US$2.3657
+US$0.1207 · +5.38%
10月12日 下午6:14 ET
盤中時間採用ET。市場資料可能有所延遲。
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
日內區間
目前US$2.245
52週區間
目前US$2.245
盤中時間採用ET。市場資料可能有所延遲。
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
日內區間
目前US$2.245
52週區間
目前US$2.245
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.57萬 USD | 4.57萬 USD | 7.54萬 USD | 6.04萬 USD | 6.03萬 USD |
| 銷貨成本 | 29.63萬 USD | 12.98萬 USD | 7.57萬 USD | 6.53萬 USD | 6.92萬 USD |
| 毛利 | −22.06萬 USD | −8.4萬 USD | −324 USD | −4854 USD | −8883 USD |
| 研究與開發 | 1.03兆 USD | 88.88萬 USD | 87.33萬 USD | 106.8萬 USD | 78.79萬 USD |
| 銷售、一般及管理費用 | 6.03兆 USD | 458.53萬 USD | 400.23萬 USD | 448.87萬 USD | 215.63萬 USD |
| 營業費用 | 683.18萬 USD | 542.9萬 USD | 487.57萬 USD | 555.67萬 USD | 294.42萬 USD |
| 利息收入 | 41.11萬 USD | 318 USD | 172 USD | 2511 USD | — |
| 利息支出 | — | 53.55萬 USD | 60.83萬 USD | 150.75萬 USD | 47.65萬 USD |
| 折舊和攤銷 | 22.74萬 USD | 19.31萬 USD | 16.27萬 USD | 14.36萬 USD | 18.64萬 USD |
| 營業利益 | −705.24萬 USD | −551.3萬 USD | −487.6萬 USD | −556.16萬 USD | −295.3萬 USD |
| 淨利 | −723.36萬 USD | −699.29萬 USD | −491.14萬 USD | −706.86萬 USD | −495.03萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
